Pharmacokinetics Study Comparing GME751 and US/EU-Approved Pembrolizumab in Stage II and III Melanoma Patients Requiring Adjuvant Therapy

The primary objective of this study is to evaluate the **pharmacokinetics** of GME751, a proposed pembrolizumab biosimilar, in comparison to United States (US)-licensed and European Union (EU)-approved Keytruda® in participants with stage II and III **melanoma** requiring adjuvant treatment. This is clinically relevant as it aims to determine the bioequivalence of the biosimilar to the reference product, which is crucial for ensuring similar efficacy and safety profiles in the treatment of melanoma.

The clinical trial involves a total of **281 participants** diagnosed with **melanoma**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the **pharmacokinetics** of GME751, a proposed pembrolizumab biosimilar, in comparison to US-licensed and EU-approved Keytruda® in participants with stage II and III melanoma requiring adjuvant treatment. This study is a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date is May 27, 2024, with an anticipated end date of March 12, 2026. The trial will involve multiple study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Participants will then be randomized to receive either the investigational product or the comparator. Follow-up visits will be scheduled at regular intervals to monitor safety, efficacy, and pharmacokinetic parameters. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted. The expected duration of participant involvement is approximately 22 months, contingent upon individual response and adherence to the study protocol. Conditions that may lead to early termination from the study include adverse events, withdrawal of consent, or protocol non-compliance. The trial aims to provide comprehensive data on the pharmacokinetic profile of the investigational product, contributing to the understanding of its potential as a therapeutic option for melanoma patients.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on May 27, 2024, with an estimated completion date of March 12, 2026. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis, adhering to the rigorous standards expected in a Phase 3 clinical trial. The study will focus on evaluating the treatment's impact on the specified medical condition, utilizing appropriate clinical methodologies to ensure the reliability and validity of the results.